Alogliptin: Concern About Hepatotoxicity?

Clinical Pharmacokinetics

Volumn 53, Issue 11, 2014, Pages 1057-1059

  Scheen, André J ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALANINE AMINOTRANSFERASE; ALOGLIPTIN; ANTIDIABETIC AGENT; ASPARTATE AMINOTRANSFERASE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; INSULIN; LIVER ENZYME; PLACEBO; GLUCAGON RECEPTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CHRONIC LIVER DISEASE; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; ENZYME BLOOD LEVEL; HUMAN; INSULIN TREATMENT; LABORATORY TEST; LETTER; LIVER FUNCTION TEST; LIVER TOXICITY; PRIORITY JOURNAL; RISK FACTOR; TOXIC HEPATITIS; TREATMENT DURATION; AGONISTS; LIVER DISEASE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; LIVER DISEASES; RECEPTORS, GLUCAGON;

EID: 84922089149     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0200-z     Document Type: Letter

References (13)

1. Scheen AJ. Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus. Clin Pharmacokinet. 2014;53(9):773–85.
2. Scott LJ. Alogliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2010;70(15):2051–72.
3. Barbehenn E. Hepatotoxicity of alogliptin (letter to the Editor). Clin Pharmacokinet. 2014. doi:10.1007/s40262-014-0199-1.
4. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35.
5. Seino Y, Yabe D. Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2014;15(6):851–63.
6. Gooßen K, Gräber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab. 2012;14(12):1061–72.
7. Dipeptidyl peptidase-4 inhibitors. LiverTox: clinical and research information on drug-induced liver injury. US National Library of Medicine. National Institute of Diabetes and Digestive and Kidney Disease. 2014. Available online from: http://livertox.nih.gov/DipeptidylPeptidase4Inhibitors.htm#overview. Accessed 30 Sept 2014.
8. Fontana RJ, Seeff LB, Andrade RJ, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology. 2010;52(2):730–42.
9. Data on file, Takeda, 2014.
10. Food and Drug Administration. Alogliptin risk management review. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000RiskR.pdf. Accessed 25 Sept 2014.
11. Chan KA, Truman A, Gurwitz JH, et al. A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. Arch Intern Med. 2003;163(6):728–34.
12. Scheen AJ. Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Saf. 2001;24(12):873–88.
13. European Medicines Agency. Vipidia (alogliptin). Committee for Medicinal Products for Human Use (CHMP) assessment report. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002182/WC500152273.pdf. Accessed 25 Sept 2014.